Table 4.
Natural history of CMA in different populations and settings, adapted from Mousan et al. [2].
| Authors/Year of Publication | Number of Subjects | Population/Study Design | Tolerance Rate | Age of Tolerance(year) |
|---|---|---|---|---|
| Høst et al., 2002 [86] | 39 (24 IgE-mediated) | General prospective birth cohort | 56% | 1 |
| 77% | 2 | |||
| 87% | 3 | |||
| 92% | 5 | |||
| 97% | 15 | |||
| Vanto et al., 2004 [44] | 162 (95 IgE-mediated) | Referral retrospective | 44% | 2 |
| 69% | 3 | |||
| 77% | 4 | |||
| Garcia-Ara et al., 2004 [32] | 66 IgE-mediated | Referral retrospective | 68% | 4 |
| Saarinen et al., 2005 [85] | 118 (75 IgE-mediated) | General prospective birth cohort | 51% | 2 |
| 74% | 5 | |||
| 85% | 8.6 | |||
| Skripak et al., 2007 [84] | 807 IgE-mediated | Referral retrospective | 19% | 4 |
| 42% | 8 | |||
| 64% | 12 | |||
| 79% | 16 | |||
| Fiocchi et al., 2008 [87] | 112 IgE-mediated | Referral retrospective | 52.7% | 5 |
| Martorell et al., 2008 [34] | 170 IgE-mediated | Referral retrospective | 82% | 4 |
| Santos et al., 2010 [47] | 139 (66 IgE-mediated) | Referral retrospective | 41% | 2 |
| Ahrens et al., 2012 [88] | 52 IgE-mediated | Referral retrospective | 61.5% | 12 |
| Elizur et al., 2012 [83] | 54 IgE-mediated | General prospective birth cohort | 57.4% | 2 |
| 65% | 4 | |||
| Wood et al., 2013 [89] | 293 IgE-mediated | Prospective | 53% | 5.5 |
| Yavuz et al., 2013 [49] | 148 IgE-mediated | Referral retrospective | 20% | 2 |
| 34% | 4 | |||
| 39% | 6 | |||
| Schoemaker et al., 2015 [21] | 55 | EuroPrevall, European population-based | 57% | 2 |
| Prospective |